Asia FX ticks down amid Fed independence worries; Aussie firm after hot CPI
STATEN ISLAND, N.Y. - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a clinical-stage biopharmaceutical company with a market capitalization of $8.49 million specializing in the development of new antibiotics, has been granted a patent in India for its DNA Polymerase IIIC Inhibitors, a class of small molecule antibiotics targeting difficult-to-treat bacterial infections. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, positioning it well for continued research and development efforts. The Indian Patent Office issued the patent in March 2025, adding to the company’s intellectual property portfolio which includes patents in the United States, Israel, and Japan.
The newly patented compounds are part of Acurx’s ACX-375C program, focusing on second-generation DNA pol IIIC inhibitors. These drugs are designed to combat a range of gram-positive bacterial infections, such as those caused by Staphylococcus aureus, including strains resistant to methicillin (MRSA), vancomycin (VRE), and Streptococcus pneumoniae (DRSP), as well as B. anthracis, an organism categorized as a bioterrorism threat.
Executive Chairman of Acurx, Robert J. DeLuccia, highlighted the significance of the patent for the company’s global strategy and mentioned the AI-supported drug discovery platform that underpins their research. With analyst price targets ranging from $1.50 to $12.00 per share, market expectations for the company’s potential remain wide-ranging. InvestingPro subscribers can access 11 additional exclusive insights about ACXP’s financial health and market position. Acurx’s lead inhibitor is ready for Phase 3 clinical trials as an oral treatment for C. difficile Infection, with other compounds in the pipeline showing potential for both oral and parenteral administration.
Acurx Pharmaceuticals is actively developing antibiotics with a focus on Gram-positive selective spectrum (GPSS®), targeting the bacterial enzyme DNA polymerase IIIC (pol IIIC) which is essential for DNA replication in gram-positive bacteria. The company’s lead product candidate, ibezapolstat, is set to enter international clinical trials for the treatment of C. difficile Infection. Additionally, Acurx is working on preclinical development of a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and an inhaled anthrax treatment.
The company cautions that forward-looking statements in the press release are subject to various factors that could cause actual results to differ materially from expectations. These include the progress and outcomes of clinical trials, regulatory approval processes, and the potential for successful marketing and distribution if approval is obtained. With the next earnings report scheduled for May 8, 2025, investors seeking comprehensive analysis can access detailed valuation metrics and financial health indicators through InvestingPro’s exclusive Research Reports, available for over 1,400 US stocks including ACXP.
This news is based on a press release statement from Acurx Pharmaceuticals, Inc.
In other recent news, Acurx Pharmaceuticals reported its fourth-quarter 2024 earnings with a narrower-than-expected loss per share, posting an EPS of -0.16, which exceeded analyst forecasts of -0.18. Despite this positive earnings surprise, the company’s cash reserves decreased significantly to $3.7 million, down from $7.5 million in 2023, indicating funding challenges. Acurx is advancing its lead candidate, Abezoprostat, for C. Difficile infection into Phase 3 clinical trials, with plans to initiate these trials in June 2025. The company has received positive regulatory guidance from both the FDA and EMA, aligning on the Phase 3 program’s requirements. The net loss for 2024 was $14.1 million, an improvement from $14.6 million in 2023, showing resilience amid ongoing sector challenges. Acurx is actively exploring partnerships and funding opportunities, including government and quasi-government sources, to support its clinical trial endeavors. The company recently closed a $2.5 million registered direct offering, further indicating its efforts to secure necessary funding. Analyst firms such as H.C. Wainwright and Alliance Global Partners have shown interest in Acurx’s strategic plans and regulatory progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.